

Daftar Pustaka

- Almeida, R.R. *et al.* (2018) "Advances in Pancreatic CT Imaging," *American Journal of Roentgenology*, 211(1), pp. 52–66. Available at: <https://doi.org/10.2214/AJR.17.18665>.
- Artinyan, A. *et al.* (2008) "The anatomic location of pancreatic cancer is a prognostic factor for survival," *HPB*, 10(5), pp. 371–376. Available at: <https://doi.org/10.1080/13651820802291233>.
- Baghbanian, M. *et al.* (2013) "Serum CA19-9 in patients with solid pancreatic mass," *Gastroenterology and Hepatology from Bed to Bench*, 6(1), pp. 32–35.
- Ballehaninna, U.K. and Chamberlain, R.S. (2011) "Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review," *Indian Journal of Surgical Oncology*, 2(2), pp. 88–100. Available at: <https://doi.org/10.1007/s13193-011-0042-1>.
- Berger, J.M. *et al.* (2023) "Clinical risk factors for ascites in metastatic pancreatic cancer," *ESMO Open*, 8(2), p. 101200. Available at: <https://doi.org/10.1016/j.esmoop.2023.101200>.
- Bilreiro, C. *et al.* (2024) "Imaging of pancreatic ductal adenocarcinoma – An update for all stages of patient management," *European Journal of Radiology Open*, 12, p. 100553. Available at: <https://doi.org/10.1016/j.ejro.2024.100553>.
- Calimano-Ramirez, L.F. *et al.* (2022) "Pancreatic acinar cell carcinoma: A comprehensive review," *World Journal of Gastroenterology*, 28(40), pp. 5827–5844. Available at: <https://doi.org/10.3748/wjg.v28.i40.5827>.
- Chiti, G. *et al.* (2021) "Imaging of Pancreatic Neuroendocrine Neoplasms," *International Journal of Environmental Research and Public Health*, 18(17), p. 8895. Available at: <https://doi.org/10.3390/ijerph18178895>.
- Cho, H.-W. *et al.* (2011) "Pancreatic Tumors: Emphasis on CT Findings and Pathologic Classification," *Korean Journal of Radiology*, 12(6), p. 731. Available at: <https://doi.org/10.3348/kjr.2011.12.6.731>.
- Coppola, A. *et al.* (2022) "Role of CA 19.9 in the Management of Resectable Pancreatic Cancer: State of the Art and Future Perspectives," *Biomedicines*, 10(9), p. 2091. Available at: <https://doi.org/10.3390/biomedicines10092091>.
- Cykowiak, M. and Krajka-Kuźniak, V. (2021) "Role of Nrf2 in Pancreatic Cancer," *Antioxidants*, 11(1), p. 98. Available at: <https://doi.org/10.3390/antiox11010098>.
- Da Costa, W.L., Oluyomi, A.O. and Thrift, A.P. (2020) "Trends in the Incidence of Pancreatic Adenocarcinoma in All 50 United States Examined Through an Age-

- Period-Cohort Analysis,” *JNCI Cancer Spectrum*, 4(4), p. pkaa033. Available at: <https://doi.org/10.1093/jncics/pkaa033>.
- Engin, H., Bilir, C. and Temi, Y. (2013) “Can Serum Tumor Markers Predict the Development of Ascites in Patients with Gastric and Pancreatic Cancer,” *Annals of Oncology*, 24, p. iv69. Available at: <https://doi.org/10.1093/annonc/mdt203.118>.
- Esmail, A. *et al.* (2025) “Impact of Tumor Location on Survival Outcomes in Pancreatic Head Versus Body/Tail Cancer: Institutional Experience,” *Cancers*, 17(11), p. 1777. Available at: <https://doi.org/10.3390/cancers17111777>.
- Farrell, J.J. (2016) “Classification of Pancreatic Lesions,” in M.S. Wagh and P.V. Draganov (eds.) *Pancreatic Masses*. Cham: Springer International Publishing, pp. 3–10. Available at: https://doi.org/10.1007/978-3-319-19677-0_1.
- Ferlay, J. *et al.* (2021) “Cancer statistics for the year 2020: An overview,” *International Journal of Cancer*, 149(4), pp. 778–789. Available at: <https://doi.org/10.1002/ijc.33588>.
- Ferrone, C.R. *et al.* (2006) “Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma,” *Journal of Clinical Oncology*, 24(18), pp. 2897–2902. Available at: <https://doi.org/10.1200/JCO.2005.05.3934>.
- Francis, I.R. (2003) “Role of CT and MR in detection and staging of pancreatic adenocarcinoma,” *Cancer Imaging*, 4(1), pp. 10–14. Available at: <https://doi.org/10.1102/1470-7330.2003.0026>.
- Globocan (2022) “global cancer observatory.” Available at: <https://gco.iarc.who.int/>.
- Gore, R.M. (2021) *Textbook of Gastrointestinal Radiology E-Book*. 5th ed. Philadelphia: Elsevier.
- Grigorescu, R.R., Husar-Sburlan, I.A. and Gheorghe, C. (2024) “Pancreatic Cancer: A Review of Risk Factors,” *Life*, 14(8), p. 980. Available at: <https://doi.org/10.3390/life14080980>.
- Hackbarth, J.S. *et al.* (2010) “Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies,” *Clinical Biochemistry*, 43(13–14), pp. 1051–1055. Available at: <https://doi.org/10.1016/j.clinbiochem.2010.05.016>.
- Han, M.Y. and Borazanci, E.H. (2023) “Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies,” *Frontiers in Oncology*, 13, p. 1138759. Available at: <https://doi.org/10.3389/fonc.2023.1138759>.

- Ishigami, K. *et al.* (2009) "Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomography," *European Journal of Radiology*, 69(1), pp. 139–146. Available at: <https://doi.org/10.1016/j.ejrad.2007.09.012>.
- Jiang, T., Zeng, Q. and He, J. (2023) "Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors?," *Translational Cancer Research*, 12(10), pp. 2932–2945. Available at: <https://doi.org/10.21037/tcr-23-1190>.
- Khasawneh, H. *et al.* (2023) "CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy: Current Status and Perspective on the Use of Radiomics," *Journal of Clinical Medicine*, 12(21), p. 6821. Available at: <https://doi.org/10.3390/jcm12216821>.
- Kim, S. *et al.* (2020) "Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases," *Scientific Reports*, 10(1), p. 8820. Available at: <https://doi.org/10.1038/s41598-020-65720-8>.
- Kim, Y.C. *et al.* (2009) "Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?," *Journal of Gastroenterology and Hepatology*, 24(12), pp. 1869–1875. Available at: <https://doi.org/10.1111/j.1440-1746.2009.05935.x>.
- Kosmahl, M. *et al.* (2005) "Pancreatic ductal adenocarcinomas with cystic features: neither rare nor uniform," *Modern Pathology*, 18(9), pp. 1157–1164. Available at: <https://doi.org/10.1038/modpathol.3800446>.
- Lee, T., Teng, T.Z.J. and Shelat, V.G. (2020) "Carbohydrate antigen 19-9 — tumor marker: Past, present, and future," *World Journal of Gastrointestinal Surgery*, 12(12), pp. 468–490. Available at: <https://doi.org/10.4240/wjgs.v12.i12.468>.
- Lei, S. *et al.* (2025) "Trends in pancreatic cancer incidence, prevalence, and survival outcomes by histological subtypes: a retrospective cohort study," *Gastroenterology Report*, 13, p. goaf030. Available at: <https://doi.org/10.1093/gastro/goaf030>.
- Li, G. *et al.* (2016) "A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in Chinese patients," *OncoTargets and Therapy*, Volume 9, pp. 5475–5481. Available at: <https://doi.org/10.2147/OTT.S99562>.
- Luchini, C. *et al.* (2020) "Malignant epithelial/exocrine tumors of the pancreas," *Pathologica*, 112(3), pp. 210–226. Available at: <https://doi.org/10.32074/1591-951X-167>.
- Mack, S. *et al.* (2025) "Pancreatic Cancer: Epidemiology, Risk Factors, and Prevention," *Onco*, 5(3), p. 37. Available at: <https://doi.org/10.3390/onco5030037>.

- Miller, F.H. *et al.* (2023) "Pancreatic Cancer and Its Mimics," *RadioGraphics*, 43(11), p. e230054. Available at: <https://doi.org/10.1148/rg.230054>.
- Molina, V. *et al.* (2012) "CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer," *Tumor Biology*, 33(3), pp. 799–807. Available at: <https://doi.org/10.1007/s13277-011-0297-8>.
- N Barbetakis and M Krikeli (2005) "Pancreatic Cancer And Malignant Pleural Effusion," *The Internet Journal of Surgery*, 6(2). Available at: <https://doi.org/10.5580/51c>.
- Pandiaraja, J. (2016) "The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of Pancreas," *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH* [Preprint]. Available at: <https://doi.org/10.7860/JCDR/2016/17106.7398>.
- Park, W., Chawla, A. and O'Reilly, E.M. (2021) "Pancreatic Cancer: A Review," *JAMA*, 326(9), p. 851. Available at: <https://doi.org/10.1001/jama.2021.13027>.
- Puckett, Y. and Garfield, K. (2025) "Pancreatic Cancer," *StatPearls*. Treasure Island (FL): StatPearls Publishing. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK518996/> (Accessed: April 13, 2025).
- Ro, C. *et al.* (2013) "Pancreatic neuroendocrine tumors: biology, diagnosis, and treatment," *Chinese Journal of Cancer*, 32(6), pp. 312–324. Available at: <https://doi.org/10.5732/cjc.012.10295>.
- Roalsø, M., Aunan, J.R. and Søreide, K. (2020) "Refined TNM-staging for pancreatic adenocarcinoma – Real progress or much ado about nothing?," *European Journal of Surgical Oncology*, 46(8), pp. 1554–1557. Available at: <https://doi.org/10.1016/j.ejso.2020.02.014>.
- Salleh, S., Thyagarajan, A. and Sahu, R.P. (2020) "Exploiting the relevance of CA 19-9 in pancreatic cancer," *Journal of Cancer Metastasis and Treatment*, 2020. Available at: <https://doi.org/10.20517/2394-4722.2020.70>.
- Santucci, N. *et al.* (2018) "CA 19–9 predicts resectability of pancreatic cancer even in jaundiced patients," *Pancreatology*, 18(6), pp. 666–670. Available at: <https://doi.org/10.1016/j.pan.2018.07.001>.
- Scarà, S., Bottoni, P. and Scatena, R. (2015) "CA 19-9: Biochemical and Clinical Aspects," in R. Scatena (ed.) *Advances in Cancer Biomarkers*. Dordrecht: Springer Netherlands (Advances in Experimental Medicine and Biology), pp. 247–260. Available at: https://doi.org/10.1007/978-94-017-7215-0_15.
- Schawkat, K. *et al.* (2020) "Pancreatic Ductal Adenocarcinoma and Its Variants: Pearls and Perils," *RadioGraphics*, 40(5), pp. 1219–1239. Available at: <https://doi.org/10.1148/rg.2020190184>.

- Seeram, E. (2010) "Computed Tomography: Physical Principles and Recent Technical Advances," *Journal of Medical Imaging and Radiation Sciences*, 41(2), pp. 87–109. Available at: <https://doi.org/10.1016/j.jmir.2010.04.001>.
- Shalita*, N. (2024) "CA19-9 as a Diagnostic Biomarker for Pancreatic Cancer," *Journal of Biomedical Research & Environmental Sciences*, 5(10), pp. 1349–1354. Available at: <https://doi.org/10.37871/jbres2022>.
- Sharma, U., Pal, D. and Prasad, R. (2014) "Alkaline Phosphatase: An Overview," *Indian Journal of Clinical Biochemistry*, 29(3), pp. 269–278. Available at: <https://doi.org/10.1007/s12291-013-0408-y>.
- Sherwood, L. (2016) *Human physiology: from cells to systems*. 9th edition. Boston, MA, USA: Cengage Learning.
- Singh, S. and Sawal, A. (2024) "Comprehensive Review on Pancreatic Head Cancer: Pathogenesis, Diagnosis, and Treatment Challenges in the Quest for Improved Survival," *Cureus* [Preprint]. Available at: <https://doi.org/10.7759/cureus.54290>.
- Smyth, C. *et al.* (2015) "CA 19-9 and ALP as potential biomarkers for pancreatic cancer risk: Analysis from a large lab test database.," *Journal of Clinical Oncology*, 33(15_suppl), pp. e15211–e15211. Available at: https://doi.org/10.1200/jco.2015.33.15_suppl.e15211.
- Soltys, S.G., Goodman, K.A. and Koong, A.C. (2007) "CyberKnife Radiosurgery for Pancreatic Cancer," in H.C. Urschel *et al.* (eds.) *Treating Tumors that Move with Respiration*. Berlin, Heidelberg: Springer Berlin Heidelberg, pp. 227–239. Available at: https://doi.org/10.1007/978-3-540-69886-9_23.
- Taher, A. *et al.* (2020) "The Postoperative Pancreas Imaging," *Journal of Gastrointestinal and Abdominal Radiology*, 3(01), pp. 087–098. Available at: <https://doi.org/10.1055/s-0040-1701747>.
- Talathi, S.S., Zimmerman, R. and Young, M. (2025) "Anatomy, Abdomen and Pelvis, Pancreas," *StatPearls*. Treasure Island (FL): StatPearls Publishing. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK532912/> (Accessed: October 11, 2025).
- Tamm, E.P. *et al.* (2003) "Diagnosis, Staging, and Surveillance of Pancreatic Cancer," *American Journal of Roentgenology*, 180(5), pp. 1311–1323. Available at: <https://doi.org/10.2214/ajr.180.5.1801311>.
- Wong, J.C. and Lu, D.S.K. (2008) "Staging of Pancreatic Adenocarcinoma by Imaging Studies," *Clinical Gastroenterology and Hepatology*, 6(12), pp. 1301–1308. Available at: <https://doi.org/10.1016/j.cgh.2008.09.014>.

- Wood, L.D. *et al.* (2022) "Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment," *Gastroenterology*, 163(2), pp. 386-402.e1. Available at: <https://doi.org/10.1053/j.gastro.2022.03.056>.
- Wu, E. *et al.* (2013) "CA 19-9 and pancreatic cancer," *Clinical Advances in Hematology & Oncology: H&O*, 11(1), pp. 53–55.
- Xiao, Y. *et al.* (2019) "Dynamic serum alkaline phosphatase is an indicator of overall survival in pancreatic cancer," *BMC Cancer*, 19(1), p. 785. Available at: <https://doi.org/10.1186/s12885-019-6004-7>.
- Zhao, P.-J. *et al.* (2025) "The value of CA19-9 and MRI features in the preoperative differential diagnosis of pancreatic ductal adenocarcinoma in periampullary carcinoma," *Abdominal Radiology*, 50(9), pp. 4160–4167. Available at: <https://doi.org/10.1007/s00261-025-04830-1>.
- Zins, M., Matos, C. and Cassinotto, C. (2018) "Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy," *Radiology*, 287(2), pp. 374–390. Available at: <https://doi.org/10.1148/radiol.2018171670>.